Buscar
Mostrando ítems 31-40 de 53
Nonalcoholic steatohepatitis pharmacotherapy and predictors of response: dual role of aminotransferases as biosensors of metabolism and biomarkers of histological improvement
(AME Publishing Company, 2019-08)
Nonalcoholic steatohepatitis (NASH)—the severe histological form of nonalcoholic fatty liver disease (NAFLD)—is regarded as a major health problem worldwide (1,2). The disease can progress to liver cirrhosis and eventually ...
Tackling the complexity of nonalcoholic steatohepatitis treatment: challenges and opportunities based on systems biology and machine learning approaches
(AME Publishing Company, 2018-12)
Nonalcoholic fatty liver disease (NAFLD) is regarded as the most frequent cause of chronic liver damage (1,2). The natural history of the disease presents a complex scenario of potential progression into severe clinical ...
Colangiocarcinoma: Actualización, diagnóstico y terapia
(Sociedad Médica de Santiago, 2008)
Glycolytic pathway candidate markers in the prognosis of oral squamous cell carcinoma: a systematic review with meta-analysis
(Corporación Universidad de la Costa, 2021)
Glycolytic pathway candidate markers in the prognosis of oral squamous cell carcinoma: a systematic review with meta-analysis
(Corporación Universidad de la Costa, 2021)
Nonalcoholic fatty liver disease
(Macmillan Publishers, 2015-12)
Nonalcoholic fatty liver disease (NAFLD) is a disorder characterized by excess accumulation of fat in hepatocytes (nonalcoholic fatty liver (NAFL)); in up to 40% of individuals, there are additional findings of portal and ...
Factores asociados a NASH severo según algoritmos FLIP/Clasificación SAF en pacientes con obesidad de un centro bariátrico de Lima, Perú
(Universidad Peruana de Ciencias Aplicadas (UPC)PE, 2022-04-30)
La obesidad es una enfermedad crónica asociada a la esteatohepatitis no alcohólica (NASH). Las etapas más avanzadas de NASH tienden a asociarse con un mayor riesgo de cirrosis y carcinoma hepatocelular. El algoritmo FLIP ...
Diseño, síntesis y efecto citotóxico de análogos de Sorafenib
(El autor, 2023)